MEIP

MEI Pharma, Inc. [MEIP] Stock Forecast

Q: What is MEI Pharma, Inc. stock symbol ?

MEI Pharma, Inc. is a US stock, located in San diego of Ca and trading under the symbol MEIP

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

MEIP Stock Summary

Earnings have grown 19.95% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

EPS has been increasing for the past 3 quarters (Quarter statements)

EPS has increased from the previous quarter and is now positive. (Quarter statements)

Became profitable this year

MEIP's dividend payments are well covered by cash flows with cash payout ratio of 27.69%.

Earnings are expected to fall -48.79% next year

MEIP has less than 1 year of cash runway

Top 10 Correlated Stocks

MEIP

In the News

01:32 11 Dec 2023 MEIP

All You Need to Know About MEI Pharma, Inc. (MEIP) Rating Upgrade to Strong Buy

MEI Pharma, Inc. (MEIP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

07:47 11 Dec 2023 MEIP

MEI Pharma, Inc. (MEIP) Q4 2023 Earnings Call Transcript

MEI Pharma, Inc. (NASDAQ:MEIP ) Q4 2023 Earnings Call Transcript September 26, 2023 5:00 PM ET Company Participants David Walsey - SVP, Corporate Affairs David Urso - President & CEO Jay File - CFO Richard Ghalie - CMO Conference Call Participants Yale Jen - Laidlaw & Company Stephen Willey - Stifel Operator Good day and welcome to the MEI Fiscal Year-End Earnings Call. My name is Gary and I will be the conference facilitator today.

12:08 11 Dec 2023 MEIP

MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates

SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced today that the companies will host a recorded joint video webcast that will be available at 8:00 am Eastern.

07:02 11 Dec 2023 MEIP

MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates

MEI Pharma, Inc. (MEIP) came out with a quarterly loss of $2.32 per share versus the Zacks Consensus Estimate of a loss of $2.60. This compares to loss of $3.40 per share a year ago.

07:35 11 Dec 2023 MEIP

MEI Pharma, Inc. (MEIP) Q2 Earnings and Revenues Top Estimates

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 150% and 237.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

06:48 11 Dec 2023 MEIP

MEI Pharma, Inc. (MEIP) Reports Q1 Loss, Lags Revenue Estimates

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 10.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

09:00 11 Dec 2023 MEIP

MEI Pharma, Inc. (MEIP) Q4 2022 Earnings Call Transcript

MEI Pharma, Inc. (NASDAQ:MEIP ) Q4 2022 Results Conference Call September 8, 2022 5:00 PM ET Company Participants David Walsey - Senior Vice President and Corporate Affairs Dan Gold - President and Chief Executive Officer Brian Drazba - Chief Financial Officer David Urso - Chief Operating Officer and General Counsel Richard Ghalie - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel Robyn Karnauskas - Truist Yale Jen - Laidlaw & Co Nick Abbott - Wells Fargo Operator Good afternoon, and welcome to the MEI Pharma 2022 Fiscal Year End Conference Call. Please be advised that the call is being recorded at the Company's request.

04:34 11 Dec 2023 MEIP

Best Penny Stocks to Buy Right Now? 3 For Your Mid-June List

Can these penny stocks continue to make gains The post Best Penny Stocks to Buy Right Now? 3 For Your Mid-June List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

07:20 11 Dec 2023 MEIP

Top Penny Stocks To Buy? 4 Biotech Stocks To Watch Now

Biotech penny stocks to watch in June. The post Top Penny Stocks To Buy?

06:49 11 Dec 2023 MEIP

MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 55.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

MEIP Financial details

Company Rating

Strong Buy

Market Cap

44.77M

Income

42.11M

Revenue

105.38M

Book val./share

12.21

Cash/share

12.34

Dividend

1.75

Dividend %

26.04%

Employees

Optionable

Shortable

Yes

Earnings

07 Feb 2024

P/E

1.06

Forward P/E

-1.37

PEG

-0.07

P/S

0.42

P/B

0.55

P/C

0.54

P/FCF

-0.8

Quick Ratio

9.6

Current Ratio

10.32

Debt / Equity

0.15

LT Debt / Equity

0.14

EPS (TTM)

6.32

EPS next Y

-4.89

EPS next Q

-1.52

EPS this Y

-52.39%

EPS next Y

-177.37%

EPS next 5Y

-146.04%

EPS last 5Y

-20.54%

Revenue last 5Y

58.27%

Revenue Q/Q

4381.61%

EPS Q/Q

-660.26%

SMA20

-9.75%

SMA50

-7.12%

SMA100

-10.25%

Inst Own

2.19%

Inst Trans

ROA

42%

ROE

89%

ROC

0.4%

Gross Margin

100%

Oper. Margin

35%

Profit Margin

40%

Payout

Shs Outstand

6.66M

Shs Float

4.94M

Target Price

52W Range

4.0-7.97

52W High

-4%

52W Low

+68%

RSI

53.12

Rel Volume

0.59

Avg Volume

59.39K

Volume

34.9K

Perf Week

9.8%

Perf Month

-4.68%

Perf Quarter

-6.28%

Perf Half Y

-8.2%

Beta

0.697

Volatility

0.22%, 0.51%

Prev Close

-0.15%

Price

6.72

Change

1.36%

MEIP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-06-30

Metric	2019-06-30	2020-06-30	2021-06-30	2022-06-30	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	4.41	6.35	7.42	7.47	7.33
Net income per share	-15.09	-10.1	-14.69	-10.04	-4.78
Operating cash flow per share	-26.4	7.52	-9.29	-8.94	-7.88
Free cash flow per share	-26.59	7.33	-9.49	-9.03	-7.88
Cash per share	66.83	40.1	44.58	28.11	15.11
Book value per share	43	17.18	12.02	9.61	3.7
Tangible book value per share	42.77	17.18	12.02	9.61	3.7
Share holders equity per share	43	17.18	12.02	9.61	3.7
Interest debt per share	-51.19	0	2.41	1.82	1.91
Market cap	56.18M	376.16M	196.19M	66.51M	43.84M
Enterprise value	46.59M	363.83M	195.94M	60.41M	39.66M
P/E ratio	-3.34	-8.17	-3.88	-1.22	-1.38
Price to sales ratio	11.43	13.01	7.68	1.63	0.9
POCF ratio	-1.91	10.98	-6.14	-1.36	-0.84
PFCF ratio	-1.9	11.27	-6	-1.35	-0.83
P/B Ratio	1.17	4.81	4.74	1.27	1.78
PTB ratio	1.17	4.81	4.74	1.27	1.78
EV to sales	9.48	12.58	7.67	1.48	0.81
Enterprise value over EBITDA	-0.63	-233.07	-2.24	-0.63	-1.04
EV to operating cash flow	-1.58	10.62	-6.13	-1.24	-0.76
EV to free cash flow	-1.57	10.9	-6	-1.23	-0.76
Earnings yield	-0.3	-0.12	-0.26	-0.82	-0.73
Free cash flow yield	-0.53	0.09	-0.17	-0.74	-1.2
Debt to equity	0	0	0.2	0.18	0.52
Debt to assets	0	0	0.05	0.05	0.11
Net debt to EBITDA	0.13	7.9	0	0.06	0.11
Current ratio	5.75	8.95	5.44	6.84	5.29
Interest coverage	0.81	0	0	-265.79	0
Income quality	1.75	-0.74	0.63	0.9	1.65
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	2.97	0.58	0.96	0.75	0.68
Research and developement to revenue	6.57	1.18	2.72	2.1	1.07
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	-0.03	0.02	0.01	0
Capex to revenue	-0.04	-0.03	-0.03	-0.01	0
Capex to depreciation	-2.71	-8.2	-2.48	-1.47	-0.09
Stock based compensation to revenue	1.34	0.24	0.4	0.21	0.07
Graham number	120.83	62.49	63.03	46.61	19.93
ROIC	-0.96	-0.31	-1.2	-1.06	-0.62
Return on tangible assets	-0.2	-0.22	-0.29	-0.31	-0.26
Graham Net	39.22	14.59	7.66	6.49	0.69
Working capital	67.9M	185.34M	134.52M	142.68M	87.19M
Tangible asset value	47.67M	78.22M	41.36M	52.41M	24.62M
Net current asset value	47.47M	77.13M	32.08M	41.7M	11.34M
Invested capital	0	0	0.2	0.18	0.52
Average receivables	2.64M	12.85M	14M	8.81M	5.06M
Average payables	4.22M	3.61M	4.4M	7.14M	7.03M
Average inventory	0	0	0	0	0
Days sales outstanding	391.66	257.78	108.38	90.08	0.64
Days payables outstanding	409.87	333.02	1.65K	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0.93	1.42	3.37	4.05	574.31
Payables turnover	0.89	1.1	0.22	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.35	-0.59	-1.22	-1.04	-1.29
Capex per share	-0.19	-0.2	-0.21	-0.09	-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q1

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.31	4.91	0.88	0.22	9.8
Net income per share	-2.57	1.54	-2.17	-1.51	8.46
Operating cash flow per share	-2.22	-2.14	-1.82	-1.7	-2.78
Free cash flow per share	-2.23	-2.14	-1.82	-1.69	-2.77
Cash per share	20.77	18.64	16.81	15.11	12.34
Book value per share	5.6	7.26	5.16	3.7	12.21
Tangible book value per share	5.6	7.26	5.16	3.7	12.21
Share holders equity per share	5.6	7.26	5.16	3.7	12.21
Interest debt per share	2.13	2.08	1.82	1.91	1.86
Market cap	51.97M	31.98M	30.65M	43.84M	46.71M
Enterprise value	51M	34.44M	34.89M	39.66M	55.72M
P/E ratio	-0.76	0.78	-0.53	-1.09	0.21
Price to sales ratio	5.95	0.98	5.2	30.09	0.72
POCF ratio	-3.52	-2.24	-2.53	-3.88	-2.53
PFCF ratio	-3.5	-2.24	-2.53	-3.89	-2.53
P/B Ratio	1.39	0.66	0.89	1.78	0.57
PTB ratio	1.39	0.66	0.89	1.78	0.57
EV to sales	5.84	1.05	5.92	27.22	0.85
Enterprise value over EBITDA	-2.65	4.04	-2.14	-3.61	1.01
EV to operating cash flow	-3.45	-2.41	-2.88	-3.51	-3.01
EV to free cash flow	-3.44	-2.41	-2.88	-3.52	-3.01
Earnings yield	-0.33	0.32	-0.47	-0.23	1.21
Free cash flow yield	-0.29	-0.45	-0.4	-0.26	-0.4
Debt to equity	0.37	0.28	0.38	0.52	0.15
Debt to assets	0.08	0.09	0.1	0.11	0.12
Net debt to EBITDA	0.05	0.29	-0.26	0.38	0.16
Current ratio	6.35	5.89	5.1	5.29	10.32
Interest coverage	-37.96	18.37	17.2	852.31	0
Income quality	0.89	-1.39	0.79	1.13	-0.33
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.86	0.26	1.22	6.84	0.1
Research and developement to revenue	2.23	0.47	2.56	1.76	0.05
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	-0.01	0	0	0.02	0
Capex to depreciation	-0.64	0	0	0.29	0.08
Stock based compensation to revenue	0.18	0.02	0.16	0.21	0.01
Graham number	17.98	15.85	15.88	11.19	48.21
ROIC	-0.29	0.14	-0.25	-0.2	0.53
Return on tangible assets	-0.1	0.07	-0.11	-0.08	0.56
Graham Net	2.69	4.39	2.35	0.69	9.35
Working capital	125.47M	110.79M	96.86M	87.19M	79.86M
Tangible asset value	37.31M	48.37M	34.35M	24.62M	81.36M
Net current asset value	22.63M	34.22M	20.65M	11.34M	68.53M
Invested capital	0.37	0.28	0.38	0.52	0.15
Average receivables	8.9M	6.73M	5.14M	2.33M	42.5K
Average payables	8.17M	6.24M	4.23M	5.26M	4.68M
Average inventory	0	0	0	0	0
Days sales outstanding	79.98	15.68	69.94	5.25	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	1.13	5.74	1.29	17.14	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.46	0.21	-0.42	-0.41	0.69
Capex per share	-0.01	0	0	0	0

MEIP Dividend History

MEIP Frequently Asked Questions

What is MEI Pharma, Inc. stock symbol ?

MEI Pharma, Inc. is a US stock , located in San diego of Ca and trading under the symbol MEIP

What is MEI Pharma, Inc. stock quote today ?

MEI Pharma, Inc. stock price is $6.72 today.

Is MEI Pharma, Inc. stock public?

Yes, MEI Pharma, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 59.39K
Market Capitalization 44.77M
Employee 46
CEO Mr. David M. Urso B.A., Esq., J.D.
Headquarters San Diego,CA,US
IPO Date 2003-12-18
Website https://www.meipharma.com

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.